SOUTH SAN FRANCISCO, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (NASDAQ:MGRM), formerly ViroLogic, Inc., announced today that William D. Young, CEO and Chairman of Monogram will present a corporate overview at the Thomas Weisel Partners Healthcare Conference 2005 at The Four Seasons Hotel in Boston, Massachusetts, on Friday, September 9, 2005 at 2:40 p.m. Eastern Time. To access the live audio broadcast, or the subsequent archived recording, log on to the investor relations section of the Company's website at http://www.monogrambio.com/ . The archived version of the webcast will be available on the Company's website for one month. About Monogram Biosciences, Inc. Monogram, formerly ViroLogic, Inc., develops and commercializes innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. Monogram's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information can be found at http://www.monogrambio.com/. FORWARD LOOKING STATEMENTS Certain statements in this press release are forward-looking, including statements regarding the activities expected to occur in connection with the name-change and stock ticker change. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the performance of our products; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for its products; whether the FDA or any other agency will decide to regulate Monogram's products or services; whether the Company will encounter problems or delays in automating its processes; whether licenses to third party technology will be available; whether Monogram is able to build brand loyalty and expand revenues; and whether Monogram will be able to raise sufficient capital when required. For a discussion of other factors that may cause Monogram's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements. DATASOURCE: Monogram Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief Financial Officer of Monogram Biosciences, +1-650-624-4576, or ; or Carolyn Bumgardner Wang of WeissComm Partners, +1-415-946-1065, or , for Monogram Biosciences Web site: http://www.virologic.com/ Web site: http://www.monogrambio.com/

Copyright